The project has signed up about 170,000 participants so far, of whom 100,000 are fully enrolled, and plans to enhance recruitment through pop-up clinics.
The FDA said it is the first test authorized to test for M. genitalium, a slow-growing bacteria that is difficult to detect with traditional laboratory methods.
The firm said it raised €55.5 million to fund the expansion of its Idylla test platform, its sales and marketing activities, and other general corporate purposes.
Three long-read assemblies — two from PacBio data alone and one from Oxford Nanopore and Illumina data — had considerably more indel errors in genes than short-read assemblies.
The company, which employs 300 people, axed 30 jobs in the US and 25 jobs from its overseas operations as it refocuses on therapeutic development.
The deal covers distribution of the SpeeDx ResistancePlus and PlexPCR assays.
The Boston-based startup will use the funds to expedite prototype development of its sample preparation technology and computational approach.
Driven by strong pharma sales, revenues increased to $715 million from $687 million in Q4 2017, besting the consensus analyst estimate of $703 million.
Researchers traced genomic, epigenomic, and expression features in lung carcinoma in situ cases that regressed or progressed to invasive lung squamous cell carcinomas.
Alere rapid diagnostics revenues were $548 million in the quarter, driven by infectious disease and cardiometabolic testing product sales.
The Belgium-based firm plans to use the proceeds to fund expansion of the Idylla test platform, sales and marketing activities, and additional general corporate purposes.
The firm will use the funds to improve market entry and expedite development of its artificial intelligence-based software that analyzes single-cell data.
Cancer Research UK has awarded nearly £60 million in funding to three US investigator-led research initiatives focused on cancer progression and drug response.
The nuclease, which comes from Bacillus hisashii, has gain-of-function mutations that facilitate robust editing in human cell lines and primary human T cells.
The researchers found that low-frequency variants in TP53 had a large effect on head circumference and volume, suggesting a previously unknown role for the gene.
Oxford Nanopore had challenged the validity of the patent, EP3045542, which relates to DNA sample preparation for PacBio's circular consensus sequencing.
An analysis of B cell adaptive immune receptor sequences in 10 individuals uncovered exceptionally diverse antibody repertoires with a subset of shared antibody clonotypes.
The clearance enables 23andMe to report on the two most common variations in the MUTYH gene influencing MAP, which increases risk of CRC development.
Last week, GenomeWeb's readers were most interested in a new study showing that a high tumor mutational can predict immunotherapy benefit across cancers.
One locus appears to be more common among individuals with Native American or East Asian ancestry and suggests there was convergent evolution of skin color among Eurasians.
LunaDNA parent company LunaPBS will combine its technology platform with Genetic Alliance's PEER system to advance patient-centric research.
A number of the genes implicated are also the targets of approved therapeutics or of ones under testing.
With its stock price languishing below $1, NantHealth has 180 days to come into compliance with Nasdaq listing rules.
A brief recap of Genetics/Genomics news the week of Jan 18, 2019: Fitbit, Cancer Genetics, Precipio and MakatiMed, Interpace Dignostics, and the World Health Organization.
Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.
University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.
The Wall Street Journal examines billing codes used by uBiome.
In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.